ANIK (Anika Therapeutics) Float Percentage Of Total Shares Outstanding: 76.02% (As of Jul. 09, 2026)


ANIK Anika Therapeutics Inc ANIK
64 GF Score
Price $16.09
GF Value $20.58
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Anika Therapeutics Float Percentage Of Total Shares Outstanding?

Anika Therapeutics ANIK -1.29% 64 Float Percentage Of Total Shares Outstanding is 76.02% as of Jul. 09, 2026. GuruFocus rates ANIK with a GF Score™ of 64/100 and a GF Value™ of $20.58 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Anika Therapeutics's float shares is 10.12 Mil. Anika Therapeutics's total shares outstanding is 13.31 Mil. Anika Therapeutics's float percentage of total shares outstanding is 76.02%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Anika Therapeutics's Insider Ownership is 11.10%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Anika Therapeutics's Institutional Ownership is 98.74%.

ANIK
64GF Score
Anika Therapeutics Inc ANIK
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anika Therapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Anika Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=10.12/13.31
=76.02%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 76.02% mean?
Anika Therapeutics (ANIK) has a Float Percentage Of Total Shares Outstanding of 76.02% as of Jul. 09, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Anika Therapeutics and its competitors.
Is Anika Therapeutics' Float Percentage Of Total Shares Outstanding too high?
Anika Therapeutics' current Float Percentage Of Total Shares Outstanding is 76.02%. Overall, Anika Therapeutics has a GF Score™ of 64/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Anika Therapeutics' Float Percentage Of Total Shares Outstanding compare to LFCR and DERM?
Anika Therapeutics' Float Percentage Of Total Shares Outstanding of 76.02% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Drug Manufacturers company?
A good Float Percentage Of Total Shares Outstanding depends on the Drug Manufacturers industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Anika Therapeutics and its competitors. Anika Therapeutics's current Float Percentage Of Total Shares Outstanding is 76.02%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anika Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Anika Therapeutics (ANIK) is currently considered Modestly Undervalued. The stock's GF Value™ is $20.58, compared to a current price of $16.09 — trading 21.8% below its estimated fair value. The current Float Percentage Of Total Shares Outstanding is 76.02%. Anika Therapeutics' overall GF Score™ is 64/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For Anika Therapeutics (ANIK), the current Float Percentage Of Total Shares Outstanding is 76.02% as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Anika Therapeutics (ANIK) Overvalued in 2026?

Based on GuruFocus' analysis, Anika Therapeutics stock appears to be undervalued. The current stock price of $16.09 is trading 21.8% below its estimated GF Value™ of $20.58. GuruFocus considers Anika Therapeutics to be Modestly Undervalued.

Key valuation signals for ANIK:

  • Float Percentage Of Total Shares Outstanding: 76.02%
  • GF Value™: $20.58 vs. price of $16.09 (21.8% below fair value)
  • GF Score™: 64/100 with 4 warning signs

No single metric tells the full story. See the ANIK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Anika Therapeutics Business Description

Other Exchanges AKP:Germany
Address 32 Wiggins Avenue, Bedford, MA, USA, 01730
Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.
64GF Score

Get the complete analysis for ANIK

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$16.09
Price
$20.58
GF Value